Market News & Trends
Retrophin Announces Cooperative Research & Development Agreement
Retrophin, Inc. recently announced it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for…
Atara Biotherapeutics Receives FDA Orphan Drug Designation
Atara Biotherapeutics, Inc. recently announced that ATA230 was granted orphan drug designation for the treatment of cytomegalovirus (CMV) viremia and disease in immunocompromised patients by…
TG Therapeutics Announces Completion of Target Enrollment in Phase 3 Trial
TG Therapeutics, Inc. recently announced that target enrollment for the UNITY-CLL Phase 3 trial has been achieved. The UNITY-CLL Phase 3 trial is a randomized…
AMRI’s Global Analytical Services Introduces Comprehensive Forced Degradation Services
AMRI’s Global Analytical Services is pleased to launch a new comprehensive forced degradation service to meet the industry demand for supporting drug substance, product including…
GE Healthcare Advances the Delivery of Cell Therapies With New Thawing Technology
GE Healthcare recently introduced the first in its VIA Thaw series, the VIA Thaw CB1000 for thawing large volumes of cell therapies cryopreserved in cryo-bags.…
AMRI Expands Sterile Production Capacity
AMRI, a global contract research, development and manufacturing organization, is expanding its sterile manufacturing capacity. The addition of an aseptic pre-filled syringe filling line at…
GSK Exercises Option Over Adaptimmune’s SPEAR T-Cell Therapy Program
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, recently announced that GlaxoSmithKline plc has exercised its option under a collaboration and license…
Novartis AG Receives First Ever FDA Approval for CAR-T
A new era in cancer treatment is now here. The US FDA recently gave the nod to Switzerland-based Novartis AG for its gene therapy cancer…
Immunovaccine Announces Achievement of Milestones in Collaboration with Zoetis
Immunovaccine Inc., a clinical-stage immuno-oncology company, recently announced the achievement of several milestones in its ongoing collaboration with global animal health company Zoetis to develop…
Genmab & Seattle Genetics to Co-Develop Tisotumab Vedotin for Solid Tumors
Genmab A/S and Seattle Genetics, Inc. recently announced that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into…
Asia-Pacific Hepatitis C Market to Surpass $8.3 Billion by 2023
The hepatitis C market across the Asia-Pacific (APAC) region, which includes India, China, Australia, South Korea and Japan, is forecast to grow from $5.3 billion…
Rexahn Pharmaceuticals Receives New US Patent
Rexahn Pharmaceuticals, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,744,167, Nanoparticulate Formulations and Compositions of Piperazine…
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation
Abeona Therapeutics Inc. recently announced the US FDA has granted Breakthrough Therapy designation status to the company’s EB-101 gene therapy program for patients with Recessive…
Sanofi Completes the Acquisition of Protein Sciences
Sanofi recently announced it has completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, CT. This completion follows Federal Trade Commission…
Huber Closes $630-Million Sale of Silica Business to Evonik
The J.M. Huber Corporation has completed the sale of the Silica business unit of Huber Engineered Materials (HEM) to Evonik Industries AG, a global specialty…
Roquette Completes Acquisition, Reinforces Ambition of Being Excipient Leader
Roquette, a global leader in innovative plant-based ingredients, recently announced it has completed the acquisition of Itacel from Blanver. Itacel is a leading player…
Dr. Christian Fischer to Succeed Uwe Röhrhoff as CEO of Gerresheimer AG
With effect from September 1, 2017, Dr. Christian Fischer (53) is to assume responsibility as Chief Executive Officer of Gerresheimer AG. He succeeds Uwe Röhrhoff…
Enteris Biopharma Doses First Woman in Phase 2a Clinical Trial
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, recently announced the first woman has been dosed in…
Jupiter Orphan Therapeutics Receives Orphan Drug Designation
Jupiter Orphan Therapeutics, Inc. recently announced it has received notification from the US Food and Drug Administration (FDA) that its Orphan Drug Designation request for…
PharmAkea Announces Successful Completion of a Phase 1 Trial
PharmAkea, Inc. recently announced it has successfully completed a Phase 1 single and multiple ascending dose (SAD/MAD) clinical study with PAT-1251, its novel, small-molecule LOXL2…
